PRESS RELEASE : Epigenomics AG Reports Financial Results for the First Quarter of 2021

DGAP-News: Epigenomics AG / Key word(s): Quarterly / Interim Statement/Quarter Results 
Epigenomics AG Reports Financial Results for the First Quarter of 2021 
2021-05-12 / 08:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Press release 
Epigenomics AG Reports Financial Results for the First Quarter of 2021 
Berlin (Germany) and San Diego, CA (U.S.A.), May 12, 2021 - Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the "Company") 
today reported financial results (IFRS, unaudited) for the first three months of 2021. 
Financial key figures 
  . Product revenue in the first quarter 2021 decreased from EUR 239 thousand to EUR 106 thousand compared to the 
    prior-year period due to lower product revenues in the United States and Europe. In the current pandemic situation, 
    many patients eligible for screening continue to postpone their screenings. 
  . Research and development costs decreased from EUR 1,603 thousand to EUR 737 thousand. 
  . Selling, general and administrative costs diminished from EUR 1,992 thousand to EUR 1,601 thousand. 
  . EBITDA before share-based payment expenses improved to EUR -985 thousand in the reporting period vs. EUR -2,641 
    thousand in the same period as the previous year 
  . The net loss for the period was EUR -1,201 thousand (Q1 2020: EUR -2,982 thousand); the net loss per share 
    decreased significantly from EUR 0.55 to EUR 0.20 compared to the same period of the previous year. 
  . Cash consumption decreased to EUR 1,401 thousand in Q1 2021 (Q1 2020: EUR 3,284 thousand). 
  . As of March 31, 2021, the Company had cash and cash equivalents (including marketable securities) of EUR 7,446 
    thousand (December 31, 2020: EUR 4,527 thousand). 
Strategic options 
Following the negative reimbursement decision by the CMS in January 2021, the management is considering various 
strategic options. As announced at the end of March, the Company is evaluating, among other things, a potential sale of 
the Company by way of a share deal (public takeover) or asset deal to one or more investors as part of an M&A 
transaction. For this purpose, a corresponding sales process has been set up and the Company is in discussions with 
several potential parties. The Company has mandated a leading international investment bank as advisor in connection 
with the sale process. 
Major events after the end of the reporting period 
  . The first conversion period for the mandatory convertible bond issued in January 2021, ran from April 1 to April 
    14, 2021. Bonds with a nominal value of EUR 4,357,606.00 have been converted into 3,961,460 new shares (ISIN 
    DE000A3H2184). Accordingly, the number of issued shares increased from 5,891,230 to 9,852,690 no-par value 
    registered shares of the Company. The Company's share capital increased correspondingly to EUR 9,852,690.00. The 
    outstanding portion of the mandatory convertible bond 2021/2024 therefore has a nominal value of EUR 1,142,394.00. 
  . In addition, on April 27, 2021, the Executive Board of Epigenomics AG resolved, with approval of the Supervisory 
    Board, to increase the company's share capital through a rights issue using the Authorized Capital 2020/II. The 
    share capital shall be increased from currently EUR 9,852,690.00 by up to EUR 1,970,537.00 to up to EUR 
    11,823,227.00 by issuing up to 1,970,537 new registered no par value shares of the Company against cash 
    contributions. The subscription price for the new shares was set at EUR 1.10. The subscription ratio is 5:1. This 
    means for each five existing shares of the Company, a subscription right for one new share will be allocated. 
    Deutsche Balaton Aktiengesellschaft, with 22.59% the largest shareholder of Epigenomics AG, has already announced 
    that it will participate in the capital increase. The capital increase serves the purpose of improving the 
    Company's liquidity position ahead of upcoming important strategic decisions. 
Outlook 2021 
Revenue 
  . The Company confirms its outlook for fiscal year 2021 and continues to expect revenue within the range of EUR 0.4 
    million to EUR 1.0 million. If the NCD decision made by CMS is successfully appealed or reversed in 2021, a change 
    in the revenue guidance would be made. 
EBITDA / Cash consumption 
  . For EBITDA before share-based payment expenses, Epigenomics forecasts a range of EUR -7.0 million to EUR -9.0 
    million. Based on the Company's 2021 business plan, cash consumption is expected to be in line with the EBITDA 
    forecast (before share-based payment expenses). 
Further Information 
The 2020 Q1 interim statement (unaudited) is available on the Epigenomics' website: https://www.epigenomics.com/ 
news-investors/financial-reports/. 
Conference call for analysts and investors 
Epigenomics AG will host a conference call for analysts and investors today at 5.00 pm (CET) / 11.00 am (EDT). The 
webcast can be accessed on the Company's website: https://www.epigenomics.com/news-investors/financial-reports/. 
The dial-in numbers for the conference call are: 
Dial-in number Germany: [phone] 
Dial-in number UK: [phone] 
Dial-in number U.S.A.: [phone] 
Participants are asked to dial in 10 minutes prior to the start of the conference call and to register using the link 
above. 
An audio replay of the conference call will be provided on the Epigenomics' website subsequently. 
 
About Epigenomics 
Epigenomics AG is a molecular diagnostics company focused on blood testing for the early detection of cancer. Based on 
its proprietary biomarker technology for the detection of methylated DNA, Epigenomics develops and markets blood tests 
for various cancer indications with high unmet medical need. Epigenomics' lead product is the blood test Epi proColon 
(R) for the early detection of colorectal cancer. Epi proColon is approved by the U.S. Food and Drug Administration 
(FDA) and is marketed in the United States and Europe as well as other selected countries. HCCBloodTest, a blood test 
for the detection of liver cancer, have received the CE Mark for marketing in Europe. 
For further information please visit www.epigenomics.com. 
 
Contact: 
Company 
Epigenomics AG, Geneststrasse 5, 10829 Berlin 
Tel [phone], Fax [phone], E-Mail: [e-mail] 
Investor Relations 
IR.on AG, Frederic Hilke, Tel [phone], E-Mail: [e-mail] 
 
Note on forward-looking statements 
This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its 
business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause 
Epigenomics AG's actual results, financial condition and performance to be materially different from any future 
results, performance or achievements expressed or implied by such statements. Epigenomics makes this announcement as of 
the date of this release and does not intend to update any forward-looking statements contained herein as a result of 
new information or future events or otherwise. 
 
=---------------------------------------------------------------------------------------------------------------------- 
2021-05-12 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Epigenomics AG 
              Geneststraße 5 
              10829 Berlin 
              Germany 
Phone:        [phone] 
Fax:          [phone] 
E-mail:       [e-mail] 
Internet:     www.epigenomics.com 
ISIN:         DE000A3H2184 
WKN:          A3H218 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1195463 
 
End of News   DGAP News Service 
=------------ 

1195463 2021-05-12

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1195463&application_name=news

(END) Dow Jones Newswires

May 12, 2021 02:01 ET (06:01 GMT)